Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference43 articles.
1. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19;Hammond;N Engl J Med,2022
2. Najjar-Debbiny R, Gronich N, et al. Effectiveness of paxlovid in reducing severe covid-19 and mortality in high risk patients. Clin Infect Dis. Published online June 2, 2022. https://doi.org/10.1093/cid/ciac443.
3. Wong CKH, Au ICH, et al. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among covid-19 inpatients during Hong Kong’s omicron BA.2 wave: an observational study. medRxiv. Lancet Infect Dis. Published online August 24, 2022. https://www.sciencedirect.com/science/article/pii/S1473309922005072?via%3Dihub
4. Ganatra S, Dani S, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with covid-19. Clin Infect Dis. Published online August 20, 2022. https://doi.org/10.1093/cid/ciac673.
5. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers;Yeh;J Acquir Immune Defic Syndr,2006
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population;JAMA Health Forum;2024-01-26
2. Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study;Frontiers in Pharmacology;2023-12-06
3. [Translated article] Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to DDIs;Farmacia Hospitalaria;2023-11
4. Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation;Prostaglandins, Leukotrienes and Essential Fatty Acids;2023-10
5. Design, synthesis and biological evaluation of chalcone derivatives as potent and orally active hCYP3A4 inhibitors;Bioorganic & Medicinal Chemistry Letters;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3